Halyard Health Inc. (HYH) Sets New 52-Week High at $37.31
Halyard Health Inc. (NYSE:HYH) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $37.31 and last traded at $37.22, with a volume of 265,439 shares trading hands. The stock had previously closed at $36.11.
A number of research analysts have issued reports on HYH shares. Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Friday, May 6th. Stifel Nicolaus boosted their price target on Halyard Health from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Tuesday, June 14th. Deutsche Bank AG boosted their price target on Halyard Health from $36.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, August 10th. Finally, TheStreet upgraded Halyard Health from a “sell” rating to a “hold” rating in a research note on Friday, July 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Halyard Health has an average rating of “Buy” and an average price target of $34.20.
The company has a 50 day moving average of $34.74 and a 200 day moving average of $30.47. The stock’s market capitalization is $1.74 billion.
Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.09. The firm earned $400 million during the quarter, compared to the consensus estimate of $383.08 million. During the same period last year, the company earned $0.52 EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities research analysts forecast that Halyard Health Inc. will post $1.82 EPS for the current fiscal year.
Other hedge funds and institutional investors have recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Halyard Health during the fourth quarter valued at about $1,369,000. BlackRock Advisors LLC boosted its position in shares of Halyard Health by 151.2% in the fourth quarter. BlackRock Advisors LLC now owns 533,462 shares of the company’s stock valued at $17,823,000 after buying an additional 321,059 shares during the period. Wells Fargo & Company MN boosted its position in shares of Halyard Health by 73.8% in the fourth quarter. Wells Fargo & Company MN now owns 581,871 shares of the company’s stock valued at $19,440,000 after buying an additional 247,075 shares during the period. Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Halyard Health during the fourth quarter valued at about $1,454,000. Finally, Mutual of America Capital Management LLC boosted its position in shares of Halyard Health by 2.8% in the fourth quarter. Mutual of America Capital Management LLC now owns 32,002 shares of the company’s stock valued at $1,069,000 after buying an additional 868 shares during the period.
Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.